PFE · News · 20261112N

GLP-1 Development Funding Deal

PFIZER INC · 2026-11-12 · Importance 53 · Surprise 42 · In source text

Blackstone Life Sciences will provide Pfizer up to $1.5 billion through 2028 to fund development of berobenatide, an investigational monthly GLP-1 receptor agonist for chronic weight management. Pfizer will retain full ownership, operational control, and decision-making authority over the drug. Blackstone may receive milestone-based payments tied to U.S. regulatory approval and commercial sales, payable over multiple years if earned. Berobenatide is in Phase III trials for obesity and related comorbidities.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
cashpositivecommitted—Pfizer entered a co-funding agreement with Blackstone Life Sciences for development of berobenatide, its investigational monthly GLP-1…
operating_incomenegativeprobable—Pfizer plans to conduct over 20 trials of berobenatide, including Phase 3 studies.
cashnegativecontingent—If earned, the milestone payments to Blackstone will be made over multiple years.